The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | ALL and CLL updates at ASCO 2021
Zaid Abdel Rahman, MD, Mayo Clinic, Jacksonville, FL, discusses highlights from the American Society of Clinical Oncology (ASCO) 2021 Virtual meeting, including the results of a study evaluating chemotherapy-free regimens in Philadelphia positive acute lymphoblastic leukemia (ALL), as well as the findings from the ZUMA-3 trial (NCT02614066), also in ALL. In addition, Dr Rahman talks on the results of a study comparing the use of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia (CLL). This interview was conducted at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
